BioAtla Virtual R&D Day: BA3071 CAB-CTLA-4 Phase 1 Data Review in Multiple Solid Tumor Types
About The Event
Join us for a Virtual R&D Day with BioAtla, featuring Omid Hamid, MD (Cedars Sinai: The Angeles Clinic and Research Institute), who will review Phase 1 dose escalation trial results for BA3071, a novel conditionally and reversibly active antibody targeting CTLA-4. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent.
A live question and answer session will follow the formal presentation.